Pasithea Therapeutics Corp. (KTTA) — Financial statements
Income statement, balance sheet, and cash flow for Pasithea Therapeutics Corp. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.02 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↓100.0% | 0.01↓70.5% | 0.02 | |
| Gross Profit | 0.00 | 0.00 | 0.00↑100.0% | -0.01↓130.2% | -0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 8↑10.9% | 7↓11.1% | 8↑203.9% | 3 | 0.00 | |
| General & Administrative Expenses | 13↑82.6% | 7 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 13↑82.6% | 7 | 0.00↓100.0% | 10 | 0.00 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 8 | 0.00↓100.0% | 5 | |
| Operating Expenses | 21↑46.4% | 14↓10.8% | 16↑27.0% | 13↑179.3% | 5 | |
| Total Costs & Expenses | 21↑46.4% | 14↓10.8% | 16↑26.9% | 13↑178.4% | 5 | |
| Operating Results | ||||||
| Operating Income | -21↓46.4% | -14↑10.8% | -16↓26.9% | -13↓179.3% | -5 | |
| Depreciation & Amortization | 0.66↑2.1% | 0.65↑0.1% | 0.65↑12629.8% | 0.01↑269.4% | 0.00 | |
| EBITDA | -20↓48.5% | -14↑11.3% | -15↓30.8% | -12↓160.2% | -5 | |
| EBIT | -21↓46.4% | -14↑10.8% | -16↓36.3% | -12↓160.2% | -5 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.33↓22.7% | 0.42 | 0.00↑100.0% | -0.00↑79.9% | -0.00 | |
| Interest Income | 0.33↓22.7% | 0.42 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.00↓79.9% | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↑100.0% | -0.86 | 0.00 | |
| Other Income / Expenses | 0.43↑24.4% | 0.35↓26.8% | 0.47↓45.2% | 0.86↓63.1% | 2 | |
| Income Before Tax | -20↓46.9% | -14↑10.3% | -16↓32.2% | -12↓439.6% | -2 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -20↓46.9% | -14↑10.3% | -16↓32.2% | -12↓439.6% | -2 | |
| Net Income from Discontinued Operations | 0.00 | 0.00↑100.0% | -0.45↑79.4% | -2 | 0.00 | |
| Net Income | -20↓46.9% | -14↑12.9% | -16↓14.5% | -14↓541.2% | -2 | |
| Bottom-Line Net Income | -20↓46.9% | -14↑10.3% | -16↓11.3% | -14↓541.2% | -2 | |
| EPS (Basic) | -2.91↑77.1% | -12.69↓0.3% | -12.65↓22.3% | -10.34↓447.1% | -1.89 | |
| EPS (Diluted) | -2.91↑77.1% | -12.69↑2.5% | -13.01↓25.8% | -10.34↓447.1% | -1.89 | |
| Weighted Average Shares | 7↑541.5% | 1↓13.1% | 1↓0.0% | 1↑9.7% | 1 | |
| Weighted Average Diluted Shares | 7↑541.5% | 1↓10.6% | 1↓2.8% | 1↑9.7% | 1 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.